Serum amyloid A (SAA) is a precursor for the amyloid A in AA type of amyloidosis. Distribution of mast cells in tissues is similar to the distribution of amyloid deposits in secondary AA-amyloidosis. Therefore, we studied whether mast cells could be involved in SAA metabolism. Human mast cell line (HMC-1) cells were cultured with recombinant human apoSAA (rhSAA), and the production of tumour necrosis factor (TNF)-α and interleukin (IL)-1β was determined by ELISA. RhSAA and human SAA (huSAA) were incubated with human chymase, tryptase or with intact human mast cell (huMC) in cultures, and degradation of SAA was followed by gel electrophoresis, liquid chromatography and mass spectrometry. SAA induced dose-dependent production of TNF-α and IL-1β in HMC-1 cells. Tryptase, chymase, and huMC granules degraded efficiently the SAA protein. Degradation of SAA by tryptase, but not by chymase, released a highly amyloidogenic N-terminal fragment of SAA. Finally, incubation of huMC with rhSAA alone resulted in degradation of SAA and formation of protofibrillar intermediates. These results suggest a pathogenic role for mast cells in AA-amyloidosis.
Introduction
The main feature of amyloidosis is deposition of proteinaceous insoluble fibrils in tissues which results in organ damage. In secondary amyloidosis or AA-amyloidosis, the fibrillar part of amyloid deposits comprises of amyloid A (AA) which is derived from the circulating precursor protein, serum amyloid A (SAA) [1] . AA-amyloidosis occurs secondary to chronic inflammatory diseases such as rheumatoid arthritis, Crohns disease, the Familial Mediterranean Fever or as a result of chronic infection [2] .
Serum level of SAA, an acute-phase protein, may be increased as much as 1000-fold during acute-phase response to inflammation, infection or trauma [3] . SAA is mainly produced in the liver but the expression of SAA mRNA and SAA protein has been demonstrated also in various other cell types [4] , in the brain tissue of Alzheimer patients [5] , and in the synovial tissue of joints [6] . SAA production is up-regulated by proinflammatory mediators, notably the interleukins IL-1 and IL-6 and the tumour necrosis factor TNF-α [7] , and conversely, SAA has been shown to induce the production of cytokines in THP-1 monocytes and in neutrophils [8] [9] [10] .
The mechanisms of amyloid formation in systemic AAamyloidosis are not fully understood but it is known that continuously elevated SAA levels are critical in the pathogenesis of this disease [11] . It has been proposed that partially degraded SAA fragments are more susceptible to fibril formation. A critical role for macrophages in degradation of SAA and in amyloid formation has been suggested [12] .
Mast cells reside in connective tissue and in mucosal membranes and are a part of the immune system. In addition to histamine, mast cells produce proinflammatory mediators, such as various cytokines [13] . Mast cells are also a rich source of serine proteases, most notably chymase and tryptase [14] . A pathogenic role for mast cells has been implicated in allergic diseases and recently also in inflammatory diseases, the prime example of which is rheumatoid arthritis [15] . Interestingly, the distribution of mast cells in tissues is quite similar to the tissue distribution of amyloid deposits [16] . For example, in renal AAor immunoglobulin light chain (AL) amyloidosis increased density of interstitial mast cells has been found in the affected kidney [17, 18] . This clustering may be due to the fact that SAA can act as a mast cell chemoattractant [19, 20] .
The aim of the present study was to investigate for any interaction between mast cells and SAA, and to elucidate whether such interaction could be involved in amyloidogenesis. We found that SAA activates HMC-1 and huMC cells which, in turn, results in the degradation of SAA into an amyloidogenic fragment and the formation of protofibrillar intermediates.
Materials and methods

Materials
Recombinant human SAA (rhSAA) was purchased from Peprotech EC Ltd. (London, UK). The amino acid sequence of rhSAA corresponds to the sequence of SAA 1α isotype except for addition of Met at the N-terminus, substitution of Asp for Asn at position 60 and substitution of His to Arg at position 71. These positions are not in the region reported to be critical for the fibrillogenesis [21] . Human Serum Amyloid A (huSAA) was purchased from The Binding Site (San Diego, CA, USA). Chymase purified from the human skin mast cells and tryptase purified from the human lung mast cells were from Calbiochem (La Jolla, CA, USA). Human albumin, Ca 2+ ionophore A23187 and monothioglyserol were from Sigma (St. Louis, MO, USA). Iscove's modified Dulbecco's medium and non-essential amino acids were from GIBCO Invitrogen Corporation (Paisley, UK). Semi-purified human myeloma IgE and goat antihuman IgE polyclonal antibody were purchased from Chemicon (Temecula, CA, USA). Human recombinant stem cell factor (SCF) and interleukins IL-4, IL-6 and IL-10 were from R&D Systems (Minneapolis, MN, USA).
Culture and stimulation of HMC-1 cells and of human mast cells
Human mast cell line (HMC-1) [22] cells were maintained in Iscove's modified Dulbecco's medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 0.1 μM non-essential amino acids, 1.2 mM monothioglycerol and 100 U/ml penicillin-100 μg/ml streptomycin at 37°C in 5% CO 2 . For cytokine assays, cells (1×10 6 cells/ml) were incubated for 24 h in the culture medium containing intact rhSAA at concentration of 3-120 μg/ml or denaturated rhSAA at 60 μg/ml or human albumin at 120 μg/ml. PMA (50 ng/ml) and Ca 2+ ionophore A23187 (0.5 μM) were used to chemically activate HMC-1 cells [23] . After stimulation, the culture medium was collected by centrifugation and cytokine concentrations were determined from the supernatants by a commercial TNF-α or IL-1β ELISA kit (R&D Systems, Minneapolis, MN, USA or BioSource Europe S.A., Nivelles, Belgium).
Human mast cells (huMCs) were cultured from cord blood or peripheral blood CD34+ progenitor cells as described [24] , with modifications. Shortly, the cord blood stem cells were cultured in Dulbecco's modified medium containing 10% heat-inactivated FCS. In addition, it was supplemented with 80 ng/ml SCF, 50 ng/ml IL-6 and 10 ng/ml IL-10 for the first 1-3 weeks, with 80 ng/ml SCF for the following 4-8 weeks, and with 80 ng/ml SCF and 10 ng/ml IL-4 after 8 weeks. The cells of peripheral blood were cultured in serum-free conditions in Dulbecco's modified medium containing 100 U/ml penicillin and 100 μg/ml streptomycin, and 100 ng/ml of SCF. After 4 weeks, 50 ng/ml of IL-6 was added to the medium, and after 8 weeks, 10 ng/ml of IL-4 was added.
For histamine release assay, the huMCs (1.7×10 5 cells/ml) were first coated with 6 μg/ml human myeloma IgE for 2 h in +37°C, after which they were washed and then incubated either with 0-120 μg/ml rhSAA for 1 h followed by incubation with 10 μg/ml goat anti-IgE for 1 h or only with 0-120 μg/ml rhSAA. After stimulation, the granule-containing cell culture medium was collected after sedimentation of the cells by gentle spinning (5 min, RT, 200×g). The histamine concentrations in the supernatants were determined by a commercial histamine ELISA kit (IBL, Hamburg, Germany).
Degradation of SAA
For enzyme digestion experiments, 6 μg of rhSAA or huSAA were incubated at +37°C with 0.01 BTEE units of human chymase and/or 3.2 mU of human tryptase in PBS pH 7.4. Samples taken after 0 and 2 h of incubation were analyzed using Tricine-SDS-PAGE [25] with 18%, 10% and 4% separating, spacing and stacking layers, respectively. The gels were prefixed with 0.2% glutaraldehyde and 30% ethanol in 0.2 M sodium acetate for 1h and then stained by Coomassie blue (BioRad, Hercules, CA, USA). In addition to gel electrophoresis, the rhSAA digests were analyzed by high performance liquid chromatography connected to a mass spectometer (HPLC-MS/MS) using a linear acetonitrile gradient (9-73% in 135 min) with PepMap C18 micro column (FUS-15-03-C18-PM, 3 μm, 100 Å) on Famos/Switchos/Ultimate HPLC system (LC-Packings, Amsterdam, Netherlands) that was connected on-line to Esquire 3000 Plus Ion-Trap-MS (Bruker Daltonics, Bremen, Germany). The enzyme activity was optimized to result in a slower degradation of rhSAA.
To study the degradation of SAA in huMC-conditioned medium, huSAA (160 μg/ml) or rhSAA (120 μg/ml) were added to the cell culture medium collected from IgE-activated huMC cultures and the mixture was incubated for 0-24 h at +37°C. Samples were collected at different time points during incubation and analyzed with 18-10-4% Tricine-SDS-PAGE or HPLC (conditions as above).
In the degradation studies with huMC cultures, the experimental conditions were similar to those in the histamine release assay, except that rhSAA was used at 100-300 μg/ml. The cell cultures were cultured in the presence of rhSAA for 4 days at +37°C, after which the culture media were collected after sedimentation of the cells by gentle spinning. Medium samples were analyzed using 16.5-10-4% Tricine-SDS-PAGE and HPLC-MS (conditions as above). A longer huMC experiment was also performed. HuMCs were cultured in the presence of rhSAA for 7 days, with additions of rhSAA on days 2, 4 and 6. The starting concentration of rhSAA was 500 μg/ml and each addition corresponded to a total concentration of 100 μg/ml. After 7 days, the cell culture medium was collected and centrifuged at 200×g to remove the cells and then at 7000×g (RT, 15 min). The supernatants were analyzed by electron microscopy. Samples were applied on Formvar-or Bioloform-coated grids (200 mesh), negatively stained with 1% uranyl acetate, air-dried and examined with Jeol 1200-EX II transmission electron microscope. The acceleration voltage of 60 kV was used.
Statistical analysis
The overall significance of differences between experimental groups was analyzed with Friedman's Nonparametric Repeated Measurements ANOVA (InStat 3 for Macintosh, Graph Pad Software, Inc.). The differences were considered to be statistically significant when P b 0.05, in which case the differences between individual experiment groups were further tested with Dunn's multiple comparisons test. The data are shown as means ± S.E.M.
Results
SAA induces cytokine production in human mast cells
First we studied the effect of SAA on cytokine production by HMC-1 cells. As demonstrated in Fig. 1 , a significant and dose-dependent increase in TNF-α and IL-1β production was observed in the presence of rhSAA. Compared to nonactivated control the highest rhSAA concentration used (120 μg/ml) increased the TNF-α production by 25-fold and IL-1β production by 38-fold, the average concentrations being 543 ± 87 and 61 ± 27 pg/ml/1×10 6 cells, respectively. The induction of TNF-α production by SAA was comparable to that observed with the combination of PMA and Ca 2+ ionophore which is a very powerful stimulus of TNF-α production in HMC-1 cells. The induction of IL-1β production by SAA was even more pronounced than observed with the combination of PMA and Ca 2+ ionophore. Interestingly the incubation of rhSAA (60 μg/ml) together with PMA and Ca 2+ ionophore resulted in further stimulation of TNF-α production to more than 100-fold compared to control, on average 2400 pg/ml/1×10 6 cells (data not shown). This suggests that the effect of SAA is mediated via a signal-transduction pathway other than calcium signalling or protein kinase C. Human albumin and heatdenatured rhSAA had no significant effect on cytokine production implicating that the effect of SAA is specific and that the native form of SAA is required for the effect.
SAA induces histamine release from human mast cells
HMC-1 cells do not possess intact IgE-receptors and therefore the effect of SAA on IgE-induced histamine release was studied in CD34+ stem cell derived human mast cells. Fig.  2 demonstrates a low but dose-dependent histamine release in the presence of increasing concentrations of rhSAA (30-120 μg/ml). Compared to SAA-induced histamine release, the histamine release observed with immunological activation was clearly more pronounced, i.e., 25-fold higher than what was released by SAA. SAA had no clear effect on the histamine release if the mast cells had been immunologically activated before the addition of the SAA (data not shown).
Degradation of SAA by mast cell derived proteases
As SAA was found to be a strong activator of mast cells we next elucidated whether mast cells could be involved in catabolism of SAA and could thus possibly contribute to generation of amyloid deposits. First, we studied the ability of purified human mast cell proteases, tryptase and chymase, which are the two major proteases of mast cells [26] , to degrade SAA. Both rhSAA and huSAA were effectively degraded when incubated with chymase or tryptase or with a combination of both (Fig. 3A) . This degradation was also followed by HPLC-MS/MS. For these experiments the enzyme activity of tryptase was lowered in order to be able to detect the very first degradation products. The MS/MS analysis of the tryptase digestion identified a peak (indicated by an asterisk; Fig. 3B ) as a compound corresponding to the mass of an N-terminal fragment (residues 3-16; SFFSFLGEAFDGAR) of rhSAA, which contains the major determinant in the amyloid formation [21] . This fragment was not detectable in the chymase digest or when both tryptase and chymase were used together.
Degradation of SAA by degranulating mast cells
Next, we studied the ability of cell culture supernatants of IgE-activated human mast cells to degrade SAA. Mast cell degranulation was induced by IgE-mediated activation as described above and supernatants were incubated with rhSAA or huSAA. The degradation of rhSAA and huSAA was followed by Tricine-SDS-PAGE. As shown in Fig. 4A , already after 2 h of incubation no intact huSAA was left and the amount of intact rhSAA diminished as a function of time. HPLC analysis of rhSAA 2 h samples revealed the presence of the same amyloidogenic N-terminal SAA fragment that was also seen when rhSAA was digested with purified tryptase.
The experiments above demonstrate that both purified mast cell granule derived enzymes and huMC-conditioned media can degrade SAA. Therefore, to demonstrate that SAA alone can induce activation of MC resulting in degradation of SAA, huMCs were cultured for 4 days in the presence of rhSAA. The collected cell culture medium was analyzed using Tricine-SDS-PAGE and HPLC-MS. Fig. 4B illustrates the degradation of SAA protein during the incubation which is indicated by the partial disappearance of intact SAA and appearance of smaller molecular weight bands. This is further demonstrated in Fig. 4C which shows the HPLC chromatograph of the digest. Together, these data suggest that addition of SAA alone to mast cell cultures is sufficient to induce degradation of the SAA protein.
Finally, we studied whether incubation of SAA with cultured mast cells can lead to amyloid formation. For this we set up an experiment where human mast cells were cultured in the continuous presence of rhSAA for 7 days. The amount of intact rhSAA in the culture during the incubation was verified by Tricine-SDS-PAGE. After 7 days cell culture media were collected and then negatively stained with uranyl acetate and examined with transmission electron microscope. As shown in Fig. 5 , fibril-like structures were found in the culture medium collected from rhSAA-stimulated huMCs (images A and B) but not in the medium that was collected from untreated cells (image C). These structures do not resemble mature amyloid fibrils as seen formed by synthetic peptides but they do possess a typical appearance of protofibrils. This finding was further supported by the fact that the N-terminal fragment of SAA could not be detected by MS analysis on the cell culture samples incubated for 4 days with SAA, suggesting that the fragment was no longer in a soluble form.
Discussion
The results of the present study show that SAA can activate human mast cells as indicated by the significant induction of TNF-α and IL-1β production. The normal SAA levels in serum vary between 1 and 5 μg/ml, but during inflammatory reaction they can be increased up to 1000-fold higher values, reaching levels of 500-1000 μg/ml. According to the present results, such levels are sufficiently high to induce cytokine production in mast cells. The mast cell-derived cytokines, again, can initiate a local inflammatory reaction, ultimately resulting in tissue and organ damage. In addition, mast cell derived cytokines can contribute to further increase in SAA levels in serum by stimulating the hepatic production.
The SAA fragments most commonly found in AA-fibrils are 68-76 amino acids in length [27] . However, the fibrils seem to be heterogeneous containing a mixture of polypeptides of different lengths [28, 29] . In particular, the N-terminal region of SAA has been shown to be a major determinant for amyloid formation [21] . In addition, other proteins, and also heparin which is a major constituent of mast cell granules, can promote amyloidogenesis [30] [31] [32] . In this study, we demonstrated that incubation of rhSAA with purified human mast cell tryptase generated a highly amyloidogenic 14-aa N-terminal fragment of SAA. Interestingly, an isolated chymotrypsin-like mast cell protease has been shown to generate the N-terminus of the Alzheimer amyloid-β protein [33] , indicating that this type of enzymes might also be involved in other type of amyloid formation. Furthermore, activation of mast cells by SAA resulted in degranulation of mast cells and thus in the release of heparin into extracellular space. In other words, the interaction of SAA with mast cells results in the production of an amyloidogenic N-terminal fragment of SAA, and in the release of heparin which might further enhance amyloid formation.
Incubation of SAA with purified human chymase or with both tryptase and chymase together resulted in the degradation of the N-terminal amyloidogenic fragment of SAA. However, incubation of rhSAA with the culture medium of activated mast cells containing the mast cell derived granules, left the amyloidogenic fragment intact. This is somewhat surprising as mast cell granules contain both tryptase and chymase. After the release of granules into the extracellular medium, tryptase is released from the exocytosed granules whereas chymase is bound to the granule matrix. Therefore, it is possible that in the presence of mast cell granules SAA is degraded mainly by tryptase, as the degradation by chymase is prevented when the carboxyterminal portion of SAA is tightly bound to the heparin proteoglycan matrix [34] . It is also noteworthy that chymase, unlike tryptase, is inactivated in vivo by several natural inhibitors [35] present in the serum. Indeed, our in vitro conditions may reflect the actual conditions in vivo, in which the natural inhibitors of chymase, present in the extracellular fluids, effectively inhibit the chymase released from activated mast cells.
During prolonged inflammation in vivo, the levels of SAA in serum are persistently high due to the hepatic production of SAA induced by proinflammatory cytokines. According to our hypothesis, SAA is degraded by mast cell-derived tryptase but at the same time new intact SAA is delivered to the site. To investigate the formation of amyloid in human mast cell cultures, we set up an experiment where SAA was added into the culture medium not only in the beginning of the incubation but also during it, with two-day intervals. This was done to ensure an excess of SAA throughout the experiment and a parallel between our experimental conditions and the conditions in vivo. EM analysis on the cell culture media revealed an extensive formation of fibril-like structures and aggregates. Interestingly, several recent papers suggest that protofibrils or small oligomers are critical for the toxic effects of amyloid [36] [37] [38] . Based on these findings, we would like to suggest that human mast cells are capable of turning SAA protein into amyloid.
Many of the tissues that are prone to develop amyloid deposits contain also abundant number of mast cells. Therefore it is reasonable to assume that there is a functional relationship between SAA and mast cells during amyloidogenesis in the affected tissues. We would like to propose that such interaction between SAA and mast cells involves the following hypothetical sequence of events. High levels of SAA activate mast cells to degranulate and to release their stores of cytoplasmic neutral proteases, notably tryptase. The tryptase-generated amyloidogenic SAA fragment can activate amyloid formation, which is further enhanced by the mast cell-derived heparin conceivably serving as an additional amyloid-enhancing factor. The SAAinduced secretion of cytokines by mast cells may contribute to the hepatic production of SAA, creating a positive-feedback loop to exist. The above outlined mast cell-dependent processing of SAA could represent an additional pathway for generation of amyloid.
